Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Biofluid Biopsies
Conferences  \  Biofluid Biopsies and Companion Diagnostics 2014  \  Biofluid Biopsies  \  Agenda  \  Thomas Krahn
RegisterLogin

Thomas Krahn's Biography


Thomas Krahn, Head of Global Biomarker Research Department, Bayer Pharma Ag

1Thomas Krahn is head of "Translational Research" at Bayer Pharma AG, which later became the global function biomarker since 2006.

After a short time as a postdoc at the University of Leuven, Belgium, he joined in 1990 as a laboratory manager in the Department of Pharmacology of Bayer AG. According to various areas of responsibility within the cardiovascular research, he took over 2002, the Head of Department of the global function "Published information" and then the department "Product Related Research Diabetes".

Thomas Krahn in 1989 his doctorate at the Ruhr University Bochum in biology with a focus Physiology and Pharmacology.

Thomas Krahn Image

Capturing and Molecular Analysis of CTCs: Potential as Predictive Biomarkers in Clinical Studies

Monday, 27 October 2014 at 14:00

Add to Calendar ▼2014-10-27 14:00:002014-10-27 15:00:00Europe/LondonCapturing and Molecular Analysis of CTCs: Potential as Predictive Biomarkers in Clinical StudiesSELECTBIOenquiries@selectbiosciences.com

Obtaining tumor tissue from cancer patients for diagnosis and biomarker assessment for patient selection is challenging. Circulating tumor cells (CTCs) may represent an attractive alternative as a “liquid biopsy” providing real-time information about the patient’s current disease state as well as response to treatment. However, capturing these rare cells from body fluids is a major challenge that still needs improvement. We are exploring technologies to capture larger amounts of tumor cells and to use their molecular profile to predict response to treatment in early clinical trials.  We will present data of a study comparing different CTC capturing technologies. For optimal comparison, CTC preparations from the same patient were used. The required high amounts of sample aliquots and CTCs were obtained e.g. by apheresis.  Today’s standard, the CellSearch® system by Veridex was performed and compared with other antigen-based methods and antigen independent methods. Downstream analysis of the isolated CTCs is performed by highly sensitive protein analysis technologies. Limited capture efficiency is tried to be tackled by cultivation of CTCs. Examples of predictive biomarkers based on CTCs capturing and subsequent molecular analysis will be shared and discussed.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonBiofluid BiopsiesSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors